Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

Clinical Infectious Diseases

Volumn 34, Issue 4, 2002, Pages 504-510

  Negredo, Eugenia ^a   Cruz, Luís ^a   Paredes, Roger ^b   Ruiz, Lidia ^b   Fumaz, Carmina R ^a   Bonjoch, Anna ^a   Gel, Silvia ^a   Tuldrà, Albert ^a   Balagué, Montserrat ^b   Johnston, Susan ^a   Arnó, Albert ^a   Jou, Antoni ^a   Tural, Cristina ^a   Sirera, Guillem ^a   Romeu, Joan ^a   Clotet, Bonaventura ^a,b  

^a Lluita Contra la SIDA Foundation   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CD4 ANTIGEN; EFAVIRENZ; GAMMA GLUTAMYLTRANSFERASE; NEVIRAPINE; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RASH; T LYMPHOCYTE; VIRUS INHIBITION;

FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; NEVIRAPINE; OXAZINES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0037082965     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/324629     Document Type: Article

References (26)

1. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-infection in adults
2. Efavirenz: Shifting the HAART paradigm in adult HIV-1 infection
3. The ATLANTIC study: A randomized open-label trial comparing two protease inhibitors-sparing antiretroviral strategies versus a standard PI-containing regimen, 48-week data
4. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS trial
5. Preliminary results of a randomized multicenter study comparing conbivir plus nelfinavir or nevirapine in HIV-infected naïve patients (COMBINE study)
6. Antiretroviral treatment simplification with nevirapine in PI-experienced patients with HIV-associated lipodystrophy: One-year prospective follow-up of a multi-centre, randomised, controlled study
7. Switch from PI to one daily NNRTI in HIV-infected patients maintaining undetectable plasma viral loads on PI-containing regimens: The maintavir study
8. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
9. A prospective open-label pilot trial of a maintenance nevirapine-containing regimen in patients with undetectable viral loads on protease inhibitors regimens for at least 6 months
10. Partial improvement of lipodystrophy after switching from HIV-1 protease inhibitors to efavirenz
11. Risk and benefits of replacing protease inhibitors with nevirapine in patients with long-term successful triple combinations
12. Evolution of lipodystrophy syndrome and lipidic profile in HIV patients after switching from protease inhibitors to efavirenz
13. A health status questionnaire using 30 items from the medical outcomes study
14. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps
15. Hidden HIV-1 drug-resistance mutations appear during sequential cycles of structured treatment interruptions (STI) in HIV-1-infected patients with long-term viral suppression (AutoVac study)
16. Cumulative risk for developing hyperlipidemia in HIV-infected patients treated with protease inhibitors
17. Severe premature coronary artery disease with protease inhibitors
18. Identification of fat redistribution/metabolic anomalies in a cohort treated by 2 NRTIs + 1 PI, and absence of significant modification following PI-substitution
19. Impact of switching from HIV-1 protease inhibitors (PI) to efavirenz (EFV) in patients with lipodystrophy
20. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
21. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
22. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors as a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
23. Impact of treatment with HIV protease inhibitors on hepatitis C viremia in patients coinfected with HIV
24. A phase III-multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz
25. Psichological impact of the trimestral alternation of triple combinations of antiretrovirals in HIV-1+ patients
26. Prospective randomized 2-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to HAART